Onkologie. 2023:17(3):175-179 | DOI: 10.36290/xon.2023.035

Small cell lung cancer, current treatment and perspectives

Miloš Pešek
Klinika pneumologie a ftizeologie, FN a LF UK v Plzni

Small cell lung cancers are among cancer diseases in which treatment outcomes have improved very little during the previous decades. In recent years, however, there has been some improvement in early as well as long-term treatment outcomes in patients with extensive-stage disease. Clinical trials using the combination of standard chemotherapy of etoposide and a platinum derivative with durvalumab, atezolizumab, and pembrolizumab have yielded positive results. The results of trials mentioned here which focused on epigenetic changes in tumour tissue and on investigating gene expression profiles hold promise in terms of possible personalization of systemic therapy.

Keywords: small cell lung cancer, chemotherapy, immune-oncological therapy, durvalumab, atezolizumab, pembrolizumab, epigenetics.

Accepted: June 12, 2023; Published: June 16, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pešek M. Small cell lung cancer, current treatment and perspectives. Onkologie. 2023;17(3):175-179. doi: 10.36290/xon.2023.035.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Wang Q, Gumus ZH, Colarosi C, et al. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening and Early Detection. Journal of Thoracic Oncology. 2023;18(1):31-46. Go to original source... Go to PubMed...
    2. Wang Q, Gümüş ZH, Colarossi C, et al. SCLC: Epidemiology, Risk Factors, Genetic Susceptibility, Molecular Pathology, Screening, and Early Detection. J Thorac Oncol. 2023 Jan;18(1):31-46. doi: 10.1016/j.jtho.2022.10.002. Epub 2022 Oct 12. PMID: 36243387. Go to original source... Go to PubMed...
    3. Dowlati A, Lipka MB, McColl K, et al. Clinical correlation of extensive-stage small-cell lung cancer genomics. Annals of Oncology. 2016;27:642-647. doi: 10.1093/annonc/mdw005. Go to original source... Go to PubMed...
    4. Ahmad I, Chufal KS, Gupta S, et al. Defining limited stage small cell lung cancer: a radiation oncologist's perspective. Case Reports. 2018. doi: bcr-2017-223708. Go to original source...
    5. Ardizzoni A, Hansen HH, Dombernowsky P, et al. Topotecan, a new active drug in the second line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J. Clin. Oncol. 1997;15:2090-2096. Go to original source... Go to PubMed...
    6. Huisman C, Postmus PE, Giaccone G, et al. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat. Rev. 1999;25:99-206. Go to original source... Go to PubMed...
    7. Lara PN, Natale RB, Crowley J, et al. Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124. J Clin Oncol. 2009;27(15):2530-2535. Go to original source... Go to PubMed...
    8. Pawel J, Schiller JH, Shepherd FA, et al. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristin for the Treatment of Recurrent Small-Cell Lung Cancer. Journal of Clinical Oncology. 1999;17:658-667. Go to original source... Go to PubMed...
    9. Kiss I, Adámková Krákorová D, Andrašina A, et al. Modrá kniha České onkologické společnosti, 29. aktualizace. Available from: https://www.linkos.cz/files/modra-kniha/22.pdf.
    10. Paz-Ares L, Chen Y, Reinmuth N, et al. Overall survival with durvalumab plus etoposide-platinum in first-line extensive-stage SCLC: results from the CASPIAN study. Journal of Thoracic Oncology. 2019;14(10):7-8. Go to original source...
    11. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overal survival update from CASPIAN. Available from: https://doi.org/10.1016/j.esmoop.2022.100408. Go to original source... Go to PubMed...
    12. Reck M, Liu SV, Mansfield AS, et al. IMpower 133: Updated overall survival (OS) analysis of first-line (1L) atezolizumab (atezo)+ carboplatin+ etoposide in extensive-stage SCLC (ES-SCLC). Annals of Oncology. 2019;30:710-711. Go to original source...
    13. Rudin CM, Kim HR, Navarro A, et al. First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results. Wienna: WCLC 2022; OA12.06. Go to original source...
    14. Wakuda K, et al. Treatment strategy for patients with relapsed small-cell lung cancer: past, present and future. Transl Lung Cancer Res. 2020;9(2):172-179. Available from: http://dx.doi.org/10.21037/tlcr.2020.03.10. Go to original source... Go to PubMed...
    15. Ready NE, Pang HH, Gu L, et al. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study - CALGB 30504 (Alliance). J Clin Oncol. 2015;33:1660-1665. Go to original source... Go to PubMed...
    16. Manzo A, Sforza V, Carillio G, et al. Lurbinectedin in small cell lung cancer. Front Oncol. 2022 Aug 30;12:932105. doi: 10.3389/fonc.2022.932105. PMID: 36110944; PMCID: PMC9469650. Go to original source... Go to PubMed...
    17. Goldman J, Cummings A, Mendenhall M, et al. Phase 2 study analysis of talazoparib (TALA) plus temozolomide (TMZ) for extensive-stage small cell lung cancer (ES-SCLC). International Association for the Study of Lung Cancer 2022 World Conference on Lung Cancer. Wienna: 2022; August 6-9, OA12.03. Go to original source...
    18. Talazoparib and low-dose temozolomide in treating participants with relapsed or refractory extensive-stage small cell lung cancer. ClinicalTrials.gov. Updated 2022;February 82. Accessed 2022; August 8. Available from: https://clinicaltrials.gov/ct2/show/NCT03672773.
    19. Pietanza MC, Waqar SN, Krug LM, et al. Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology. 2018 Aug 10;36(23):2386-2394. doi: 10.1200/JCO.2018.77.7672. Epub 2018 Jun 15. PMID: 29906251; PMCID: PMC6085179. Available from: http://ascopubs.org/doi/full/10.1200/JCO.2018.77.7672. Go to original source... Go to PubMed...
    20. Farago AF, Yeap BY, Stanzione M. Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. Cancer Discov. 2019;9:1372-87. doi: 10.1158/2159-8290.CD-19-0582. Go to original source... Go to PubMed...
    21. Ma S, He Z, Wang L, et al. Sintilimab plus anlotinib as second or further-line therapy for small cell lung cancer: An objective performance trial. 2022 ASCO Annual Meeting, Meeting. Abstract 8516. Go to original source...
    22. Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021 March; 08;39(3):346-360.e7. doi:10.1016/j.ccell.2020.12.014 Go to original source... Go to PubMed...
    23. Park S, Noh JM, Choi LY, et al. Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer. European Journal of Cancer. 2022;169:42-53. Available from: https://doi.org/10.1016/j.ejca.2022.03.034. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.